To further explore this drug-induced change in CSC character, we employed a commercially available antibody to assess levels of CD44v6, a CSC-associated isoform of CD44 that promotes tumor cell motility and is correlated with poor prognosis in breast cancer patients [32–34]. The gene discussed is CD44; the disease is breast carcinoma.